Postoperative whole breast radiation therapy (WBRT) after breast conserving surgery (BCS) is considered the standard of care for early-stage breast cancer (EBC) patients. In recent population-based studies long-term overall survival (OS) might even be better than that following mastectomy without radiotherapy (RT) (1,2). Overall, WBRT halves the 10-year rate of any breast cancer recurrence and reduces by about one sixth the 15-year breast cancer-related mortality (3). Nevertheless, the absolute reduction in the rate of relapse and cancer mortality are to some extent proportionally affected by patient- and tumor-related characteristics including age, grade, nodal involvement and estrogen receptor status, calling for the need of tailoring clinical indications for WBRT (3).

Killander et al. recently reported the long-term results of the SweBCG 91 RT randomized phase III trial, investigating the option to omit WBRT for selected EBC (4). Clinical T1–T2N0M0 patients were randomly assigned to receive or not WBRT (48–54 Gy in 24–27 fractions) after BCS. Adjuvant systemic therapy was prescribed for stage II patients according to regional treatment guidelines. Among the 1,187 randomized patients, only 84 received tamoxifen (47 vs. 37 in the control and RT arms, respectively) and 22 CMF chemotherapy (13 vs. 9) (4). After a median follow-up of 15.6 years, patients without WBRT had a significantly higher ipsilateral breast tumor recurrence risk (IBTR) (23.9%), compared to irradiated patients (11.5%) and a lower recurrence-free survival (51.7% vs. 60.4%). OS did not significantly differ (68.4% vs. 71.1%) (4).

The role of WBRT after BCS has been extensively documented in several historical randomized studies, carried out both in Europe and in the USA, showing a significant increase in IBTR rates for patients not receiving RT (5-9). Local relapses at 5 years were observed to rise from 2–20% with WBRT to 27–42% without. However, none of these trials, including SweBCG 91 RT, were able to demonstrate an OS benefit by the addition of WBRT. Moreover, the observation that certain subsets of patients may have a lower risk of IBTR according to specific tumor- and patient-related characteristics, led to initiatives to selectively decrease the overall therapeutic burden in tailored subgroups of EBC (10). As for example in the Milan III trial, the IBTR rates in the no WBRT group were 7.4% at 10 years below 45 years of age, 3.1% in the age range 46–55 years, 1.7% for 56–65 years and equal to the WBRT arm over 65 years, age was often used as the most important discriminating factor (11).

Ideally, individualized cancer therapy should allow for treatment option selection according to clinical as well as biological characteristics, favoring the minimally
required therapeutic package to achieve adequate tumor control with acceptable toxicity and optimal long-term quality of life (12). This is particularly topical in “low-risk” breast cancer patients. Therefore, several studies investigated the potentials of de-intensification of treatment in this subgroup. In the CALGB 9343 trial, women aged ≥70 years with estrogen-receptor positive and clinical stage I (cT1N0M0) disease were randomized to receive WBRT + tamoxifen or exclusive tamoxifen as adjuvant treatment after BCS. Multiple endpoints were investigated (time to local and regional recurrence, rate of salvage mastectomies, time to distant failure and breast cancer-specific and OS). At 5 years, the IBTR rate was higher for patients having WBRT omitted (4% vs. 1%), while all other endpoints were not significantly different. The arm submitted to tamoxifen alone had better cosmetic outcomes and lower adverse effects (13). Similar findings were observed in the PRIME II study, where low-risk EBC patients aged 65 years or older [positive hormone receptors; axillary node negative; clinical T1–T2 disease up to 3 cm, grade 3 or lymphovascular invasion (LVI)] but not both, and clear margins after BCS and receiving adjuvant endocrine therapy were randomized to conventionally fractionated or hypofractionated WBRT vs. no radiation (14). The rates of IBTR were 1.3% for WBRT and 4.1% for the no radiation arm at 5 years, with a global hazard ratio (HR) of 5.19. Regional, distant and contralateral breast relapses and breast cancer-related mortality were not different. An Italian study, with similar design and a 9-year median observation time, found similar rates of IBTR (3.4 for WBRT vs. 4.4 for no radiation) and OS (81.4% vs. 83.7%) in unifocal breast cancer <25 mm, with 0–3 positive axillary nodes and no extensive intraductal component or LVI (15).

Notwithstanding these studies, the identification of the most appropriate EBC category to be offered de-intensification with WBRT omission remains a challenge. This is confirmed by the data reported in the SweBCG 91 RT trial, where the 15-year cumulative incidence of IBTR in patients without WBRT ranged from 16.7% to 28% among subgroups within different categories based on age, tumor size, hormonal receptor status and method of diagnosis (4). More interestingly, in low-risk patients (>64 years, <21 mm sized tumor, positive oestrogen and progesterone receptor) the cumulative reduction in IBTR rates following WBRT was even higher than in the whole population (IBRT: 25.9% for no WBRT arm vs. 5.3% for the radiation arm). The explanation why no influence of the omission of WBRT on OS was detected might be that follow-up is still too short, the low intensity of adjuvant systemic therapy given initially and/or the effectiveness of salvage therapy after BCS alone. Moreover, elderly low-risk EBC form a particular population with a high burden of competing causes of death. However, in general, preventing a local relapse has clinical meaningfulness (3) and there is a need for a careful clinical decision-making process before omitting WBRT, even in low-risk EBC and even without demonstration of a clear impact of WBRT on OS in this setting.

The importance of endocrine therapy in patients having WBRT omitted was shown in the German Breast Study Group (GBSG) trial, where the crude risk of local recurrence at 10 years was 7–10% in patients treated either with BCS and WBRT, BCS and tamoxifen, or BCS and both, but was 34% in those treated with BCS alone (16). However, as treatment safety and quality of life are also crucial endpoints, we should also question the need for adjuvant systemic therapy in low-risk EBC. Endocrine therapy may be associated with an increased risk for osteoporosis with skeletal related events, cardiovascular disease, sexual dysfunction and even neurocognitive effects (10). Moreover the impact of hormonal therapy in terms of OS in post-menopausal patients has yet to be confirmed with even compliance to treatment being challenging, as only 35–60% of women accomplish a full 5-year adjuvant program (10). Overall, the side-effects of adjuvant systemic therapy are expected to outweigh those of WBRT, especially as new developments in the field of radiation oncology substantially decreased the burden of radiation therapy (10). Hypofractionated schedules of WBRT and accelerated partial breast irradiation provide new options to decrease overall treatment time, cost, inconvenience, and toxicity of postoperative radiation (17–19).

The results of the SweBCG 91 RT trial and others confirm that clinical and pathologic selection of seemingly low-risk features like age for omission of radiation have reached their limit of usefulness. A selection based on biology of the tumor may be more fruitful in the future. Liu et al. conducted a retrospective subgroup analysis on 501 of 769 available blocks from the larger Canadian prospective trial that had shown a significant benefit to WBRT after BCS and tamoxifen (20). They conducted intrinsic subtyping and showed that luminal subtypes seemed to derive less benefit from WBRT (luminal A HR: 0.40; luminal B HR: 0.51) than high-risk subtypes of HER-2 or triple negative (HR: 0.13), however without reaching statistical significance. Additional studies in North
America and Europe that will study the use of subtyping for EBC in clinically low-risk women by receptor expression, genomic expression or signature assays to study omission of radiation include the LUMINA, IDEA, PRECISION and PRIMITIME trials (21).

Conclusion: the selection of the most appropriate treatment for low-risk breast cancer patients should take into account not only risk for local relapse or impact on survival, but also the treatment-related toxicity profile, patient quality of life, psycho-social issues and cost-effectiveness. Biological and molecular patterns should be investigated to assist in the clinical decision-making process. Composite endpoints and validated evaluation tools are mandatory for comparative evaluation of treatments and appropriate allocation of future patients. The quest to identify which EBC patients can forego WBRT after BCS remains to be accomplished. Simple questions may lead to complicated answers but using a holistic approach on therapeutic modalities and clinical endpoints we may achieve simplicity through a resolution of complexity, with a consequent benefit for breast cancer patients.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References


